Immunomic Therapeutics (IT), which HLB signed an investment and 51% stake acquisition on January 30, said that several biopharmaceutical companies in the United States have requested the development of a COVID-19 vaccine, and have begun developing the vaccine. As IT's immune vaccine platform technology, Universal Intracellular Targeted Expression (UNITE), was highlighted as a technology optimized for COVID-19 vaccine development and as they received proposals for co-development of vaccines from a number of US bio companies and developed COVID-19 vaccine, they decided to apply platform technology.

An IT official said, "since waiting funds for COVID-19 vaccine development are constantly increasing, we may start developing COVID-19 vaccine with a government subsidy.”

Director Hyuk Joo Chi, who led the acquisition of IT, said, “IT's immune vaccine platform technology is a platform optimized for mutated viruses.” and added, "We planned to focus on developing brain tumor treatment based on this platform, but we expect IT's excellent vaccine platform technology to be properly utilized for vaccine development for all people, without disrupting brain tumor treatment development."